Figure 5.
Clinical implication of the proportion of ASCs. (A, C) Compared to an ASC ratio of <0.1, an ASC ratio of >0.1 in the AML patients group resulted in a shorter overall survival, similar to that observed in cytogenetic risk groups, albeit without statistical significance (p = 0.211). (B, D) There was no statistically significant difference in relapse-free survival with respect to ASC ratio.